These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 27456941

  • 1. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program.
    Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, Ryoo BY, Park SR, Kang YK.
    Cancer Res Treat; 2017 Apr; 49(2):350-357. PubMed ID: 27456941
    [Abstract] [Full Text] [Related]

  • 2. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ, Ryu MH, Yoo C, Beck MY, Ma JE, Kang YK.
    Oncologist; 2019 Nov; 24(11):e1212-e1218. PubMed ID: 31036770
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators.
    Lancet; 2013 Jan 26; 381(9863):295-302. PubMed ID: 23177515
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo.
    Poole CD, Connolly MP, Chang J, Currie CJ.
    Gastric Cancer; 2015 Jul 26; 18(3):627-34. PubMed ID: 24957256
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
    Crona DJ, Keisler MD, Walko CM.
    Ann Pharmacother; 2013 Dec 26; 47(12):1685-96. PubMed ID: 24259629
    [Abstract] [Full Text] [Related]

  • 11. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
    Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D, PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).
    Lancet Oncol; 2016 May 26; 17(5):632-41. PubMed ID: 27068858
    [Abstract] [Full Text] [Related]

  • 12. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.
    Drug Des Devel Ther; 2014 May 26; 8():2061-7. PubMed ID: 25378911
    [Abstract] [Full Text] [Related]

  • 13. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.
    Eur J Cancer; 2014 Mar 26; 50(5):981-6. PubMed ID: 24388774
    [Abstract] [Full Text] [Related]

  • 14. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
    Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S.
    Clin Cancer Res; 2019 Dec 15; 25(24):7287-7293. PubMed ID: 31471313
    [Abstract] [Full Text] [Related]

  • 15. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
    Rutkowski P, Stępniak J.
    Expert Opin Drug Saf; 2016 Jan 15; 15(1):105-16. PubMed ID: 26651387
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Ohkubo S, Nishida T.
    Eur J Cancer; 2019 Nov 15; 121():29-39. PubMed ID: 31536852
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [A case of a gastrointestinal stromal tumor of the rectum effectively treated with continuously-administered regorafenib after failure of imatinib and sunitinib].
    Kajiura S, Hosokawa A, Nanjyo S, Nakada N, Ando T, Sugiyama T.
    Nihon Shokakibyo Gakkai Zasshi; 2016 Apr 15; 113(4):655-61. PubMed ID: 27052395
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.